Clinical Trial Update: Study of Anlotinib in Patients With Differentiated Thyroid Cancer(ALTER01032) [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update for Anlotinib in differentiated thyroid cancer across Phase 2 and Phase 3 stages.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Differentiated Thyroid Cancer

Drugs mentioned

• Anlotinib (anlotinib)

Snippet

Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Conditions: Differentiated Thyroid Cancer | Phase 2, Phase 3 | Status: UNKNOWN